Free Trial

Morgan Stanley's Rating of Alnylam Pharmaceuticals on 10/30/2026

On October 30, 2026, Morgan Stanley updated its outlook on Alnylam Pharmaceuticals (NASDAQ:ALNY) with the action "Lower Price Target", setting a price target of $240.00. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Morgan Stanley

DateCompanyAction
10/30/2026
Altria Group, Inc. stock logo
MO
Altria Group
Boost Price Target
10/30/2026
Amazon.com, Inc. stock logo
AMZN
Amazon.com
Lower Price Target
10/30/2026
Arxis, Inc. stock logo
ARXS
Arxis
Boost Price Target
10/30/2026
Bandwidth Inc. stock logo
BAND
Bandwidth
Boost Price Target
10/30/2026
BorgWarner Inc. stock logo
BWA
BorgWarner
Lower Price Target
10/30/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Boost Price Target
More Ratings From Morgan Stanley